Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Trevi Therapeutics hires three new executives

New Haven-based Trevi Therapeutics has named three new high-level leaders. “We are pleased to welcome Shashank Rohatagi, Farrell Simon, and Kathy Takaki to our management team...

| By Kelley Gipson

COVID-19 trials connect Yale to its community

Last August, the Yale Center for Clinical Investigation began participating in a clinical trial for a coronavirus vaccine being developed by the pharmaceutical company Pfizer...

| By Kelley Gipson

New Haven’s Arvinas extends drug pipeline

New Haven biotech Arvinas has unveiled five new preclinical programs that aim to treat various types of cancer and a fatal neurological disorder. Arvinas’s drugs...

| By Kelley Gipson

Craig Crews of Yale/Arvinas awarded Wieland Prize

Yale’s Craig Crews has been awarded the international Heinrich Wieland Prize for his discovery of new methods to target disease-causing proteins, the Boehringer Ingelheim Foundation...

| By Kelley Gipson

Vanessa subsidiary honored in Hungary

Vanessa Research reports that its subsidiary, HGA Biomed Pharmaceutical Manufacturing Ltd. (HGA), based in Kaposvár, Hungary, was awarded a prestigious Remembrance Medal. HGA was one...

| By Kelley Gipson

Azitra $17 million Series B led by Bayer

Branford biotech Azitra has doubled its lifetime venture capital fundraising with a $17 million round led by the investment arm of pharma giant Bayer. Azitra...

| By Kelley Gipson

SpringWorks closes common stock offering

SpringWorks Therapeutics reports the closing of its underwritten public offering of 5,637,254 shares of its common stock at a public offering price of $51.00 per share....

| By Kelley Gipson

BioCT welcomes new member Pangolin Therapeutics

Pangolin Therapeutics is a chemistry-driven platform company using Yale Professor and Co-founder Andrew Miranker’s PangomerTM technology to design novel small molecule therapeutics targeting mis-assembly of...